Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.31
(
-0.34%
)
Bitcoin
74,236.01
(
0.40%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bio_pete post# 138364

Wednesday, 03/07/2012 2:12:10 PM

Wednesday, March 07, 2012 2:12:10 PM

Post# of 257253
Teva’s thrice-weekly Copaxone will be reviewed under an NDA. If approved, it could cannibalize some of the market for regular Copaxone, including the generic versions; however, thrice-weekly Copaxone will require an explicit prescription and won’t be substitutable for an Rx written for regular Copaxone.

I don't have an answer for the question in your second paragraph.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now